{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "KRW", "marketState": "PREPRE", "exchangeTimezoneShortName": "KST", "gmtOffSetMilliseconds": 32400000, "esgPopulated": false, "regularMarketChangePercent": -2.5723472, "regularMarketPrice": 9090.0, "exchange": "KSC", "shortName": "Pharmicell", "longName": "Pharmicell Co., Ltd.", "messageBoardId": "finmb_20384543", "exchangeTimezoneName": "Asia/Seoul", "market": "kr_market", "regularMarketTime": 1683873014, "regularMarketDayHigh": 9330.0, "regularMarketDayRange": "9090.0 - 9330.0", "regularMarketDayLow": 9090.0, "regularMarketVolume": 195462, "regularMarketPreviousClose": 9330.0, "bid": 9070.0, "ask": 9190.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "KSE", "financialCurrency": "KRW", "regularMarketOpen": 9270.0, "averageDailyVolume3Month": 332817, "averageDailyVolume10Day": 269291, "fiftyTwoWeekLowChange": 520.0, "fiftyTwoWeekLowChangePercent": 0.06067678, "fiftyTwoWeekRange": "8570.0 - 16450.0", "fiftyTwoWeekHighChange": -7360.0, "fiftyTwoWeekHighChangePercent": -0.44741642, "fiftyTwoWeekLow": 8570.0, "fiftyTwoWeekHigh": 16450.0, "earningsTimestamp": 1675681140, "earningsTimestampStart": 1684148340, "earningsTimestampEnd": 1685102400, "sharesOutstanding": 60004000, "fiftyDayAverage": 9273.6, "fiftyDayAverageChange": -183.59961, "fiftyDayAverageChangePercent": -0.019798096, "twoHundredDayAverage": 10487.1, "twoHundredDayAverageChange": -1397.0996, "twoHundredDayAverageChangePercent": -0.13322078, "marketCap": 559837675520, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "1.0 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 946944000000, "priceHint": 2, "regularMarketChange": -240.0, "symbol": "005690.KS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Ssangbong Building", "address2": "7th Floor 874 Unju-ro Gangnam-gu", "city": "Seoul", "country": "South Korea", "phone": "82 2 3496 0114", "fax": "82 2 3496 0159", "website": "https://www.pharmicell.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.", "companyOfficers": [{"maxAge": 1, "name": "Hyun-Soo  Kim", "age": 58, "title": "Chief Exec. Officer and Inside Director", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}